Technology scouting at Bayer Healthcare

  • 2,154 views
Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
2,154
On Slideshare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
52
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Workshop Czech Republic Pharma TechTransfer 11th of October 2012TECHNOLOGY SCOUTING (TS) –we serve your needsDr. Jörg KnäbleinTECHNOLOGY SCOUTINGBayer HealthCare Pharmaceuticals; Berlin, S107, 01, 117Phone: +49 30 468-1 6852; Fax: +49 30 468-9 6852Mobile: +49 160 972 06850E-mail: joerg.knaeblein@bayer.comWeb: http://www.bayer.com
  • 2. TS – we serve your needsTECHNOLOGY SCOUTING (TS) – we serve your needs Topics and keywords for external search performed by TECHNOLOGY SCOUTING for focused search in academia: ANIMAL MODELS ●Preamble ●Search criteria BIOBANKING and BIOMARKER ●Preamble ●Search criteria TRG CARDIOLOGY ●Acute Care Research (ACS, PAOD, Ischemic Stroke, DIC, ALI/ARDS) ●Heart Diseases (Heart Failure, Atrial Fibrillation, Cardioprotection) ●Kidney Diseases (Diabetic Nephropathy, CKD, Acute Renal Insufficiency) ●Vascular Disease (Pulmonary Hypertension) ●Hemoglobinopathies (Sickle Cell Disease, Beta-Thalassemia, Hemophilia A and B) TRG ONCOLOGY / GYNOGOLOGICAL THERAPIES ●Cell cycle / Survival Signaling (Cell cycle inhibition, Induction of apoptosis) ●Chromatin Modulation and OncoGenomics (Transcription and chromatin modulators) ●Tumor Metabolism (Inhibition of tumor metabolism and Selective targeting) ●Cancer Immune Therapy and Antibody Drug Conjugates (neutralize immunosuppression, selective killing) ●Hyper-proliferative Diseases (Uterine fibroids, and Endometriosis / adenomyosis uteri) CORPORATE INFORMATION ●Reasons to Partner with Bayer ●Overview: Bayer HealthCareDr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing#* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 3. TS – we serve your needs Animal ModelsDr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing#* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 4. TS – we serve your 1 needs /2 Animal models (transgenic, syngeneic, knock-out, knock-in, xenografts, orthotrop) As a research-based pharmaceutical company, Bayer Healthcare Pharmaceuticals is aware of the ethical issues inherent to research with animal models. All experiments performed at Bayer Healthcare Pharmaceuticals are in accordance with guidelines of the German and European codes for animal experiments. We are collaborating with providers and scientific institutes who are key opinion leaders in their field and employing best practice to establish animal models characterized by minimal burden, high predictability and a high level of feasibility. External search: in-licensing/scientific collaborations on disease-relevant & predictive animal models for☑ TRG ONCOLOGY / GYNECOLOGICAL THERAPIES (updated 06-2012) ● Models of the following indications: gastric, prostate, head & neck, melanoma, colon, bladder, ovarian, triple-negative breast (TNB) cancer, including the aspects of metastasis, e.g. models of brain/bone metastasis due to lung, breast and prostate tumors ● Models refractory to clinically approved therapies (e.g. Tarceva-resistant lung CA, Herceptin-resistant mamma CA, Avastin-resistant/insensitive tumors, Taxane-resistant tumor models) ● Models addressing the topics “tumor metabolism” and “anti-tumor immune responses” ● 3D-in-vitro technologies, Cell/cell & Cell/ECM interactions, “sprouting” or “microenvironment” for tumor growth studies ● Gynecological Indications: uterine fibroids, endometriosis / adenomyosis uteri; dysfunctional uterine bleeding ● Animal models for GT (rat, mouse, primate): uterine fibroids, endometriosis / adenomyosis, human xenografts for uterine fibroids & endometriosis, pain in endometriosis, dysmenorrhea, dysfunctional bleeding ● GT Mechanisms: transgenic & K.O. animals targeting proteins related to proliferative, extra cellular matrix, angiogenic, inflammatory/painful or menorrhagic events in endometriosis or uterine fibroids Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 5. TS – we serve your 2 needs /2 Animal models (transgenic, syngeneic, knock-out, knock-in, xenografts, orthotrop) As a research-based pharmaceutical company, Bayer Healthcare Pharmaceuticals is aware of the ethical issues inherent to research with animal models. All experiments performed at Bayer Healthcare Pharmaceuticals are in accordance with guidelines of the German and European codes for animal experiments. We are collaborating with providers and scientific institutes who are key opinion leaders in their field and employing best practice to establish animal models characterized by minimal burden, high predictability and a high level of feasibility. External search: in-licensing/scientific collaborations on disease-relevant & predictive animal models for☑ TRG CARDIOLOGY (updated 06-2012) ●Short-term animal models e.g. innovative imaging techniques for PAOD and ischemic stroke ●Animal models with respect to development state for thrombotic disorders mimicking high risk patients ●Animal models with underlying cause Acute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS) ●Animal models mirroring sec. pulmonary Hypertension (e.g. PH/COPD) ●Animal models for on-line tracking of Heart Failure development and therapy success ●Animal models mirroring Atrial Fibrillation (AF) ●Animal models of acute and chronic kidney injury, diabetic nephropathy ●Ischemic stroke (prevention) models ●Bleeding models Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 6. TS – we serve your needs Biobanking and BiomarkerDr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing#* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 7. TS – we serve your needs Human specimen-based Research (Oncology / Gynecological Therapies,☑ Cardiovascular) Two lines of pharmaceutical research build upon access to human specimens, target identification and validation, and biomarker validation and qualification. E. g. in oncology, comparing the expression profile of a diseased tissue with that of a normal adjacent sample might lead to novel ideas for a targeted therapy. Comparing the protein content of a tissue sample with a peripheral blood sample in ELISA measurements might lead to less invasive diagnostic possibilities, i. e. biomarker validation (there is much lower interest in techniques for identifying biomarkers). As a research-based pharmaceutical company, Bayer Healthcare Pharmaceuticals is aware of the ethical issues inherent to this kind of research and is collaborating with clinicians who are key opinion leaders in their field employing best practice (e. g., asking for IRB vote and patients informed consent). A win-win situation exists where we are accepted as scientific research partner, e. g. offering access to analytical measurements for joint, peer-reviewed publications. Focus of external search is on scientific collaborations for☑ Oncology/Gynecological Therapies (updated 06-2012) ●the big five indications breast, colon, lung, ovarian, prostate (in particular the process of metastasis), as well as gastric, head & neck, melanoma, bladder, and triple-negative breast (TNB) cancer ●refractory to targeted therapy (e. g. Tarceva-resistant lung CA, Herceptin-resistant mamma CA, Avastin- resistent/insensitive tumors, Taxane-resistant tumor models) ●Tissue from endometriosis / adenomyosis uteri patients and respective biomarkers☑ Cardiovascular (updated 06-2012) ●Pulmonary Arterial Hypertension, Chronic Obstructive Pulmonary Disease (PAH, COPD), ACS, Kidney Failure, Peripheral Arterial Occlusion Disease (PAOD, different stages), ALI, ARDS, AKI ●Heart (cardiomyopathy of different NYHA classes); Atrial Fibrillation (AF) ●Thrombotic disorders, Acute Lung Injury, ARDS, Acute Kidney Injury Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 8. TS – we serve your needs Cardiology (updated 06-2012)Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing#* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 9. TS – we serve your needs CARDIOLOGY –☑ Acute Care Research (ACS, PAOD, Ischemic Stroke, DIC, ALI/ARDS) Bayer Healthcare Pharmaceuticals’ goal with its Cardiology business is to sustainable protect people‘s heart and bloodstream, because Cardiovascular Diseases have become a severe problem in our society. Early diagnosis and therapy of cardiovascular diseases plays a significant role – this is why our research concentrates on innovative approaches for several heart and vascular diseases as well as anti-coagulants. As a research-based pharmaceutical company, Bayer Healthcare Pharmaceuticals continues to prevent occlusion of blood vessels (thrombosis), thromboembolism (e.g. lung embolism) or dissolving clots (peripheral arterial occlusion) thereby focusing on novel treatment approaches with a balanced risk-benefit profile. Moreover, novel approaches in cardiovascular specialty indications (acute and intensive care) are of high interest to reduce the high unmet need in emergency rooms or intensive care units. Focus of external search is on proprietary (small and biological) molecules (e.g. inhibitors), innovative approaches, new mechanism-of-action, state-of-the-art in-vitro, in-vivo and ex-vivo pharmacology models, and biomarkers for Acute Coronary Syndromes (ACS) anticoagulation, antiplatelets ●Chronic treatment, high risk patients ●No acute therapy ●New biomarkers Peripheral Arterial Occlusive Disease (PAOD), Ischemic Stroke (IS) prevention, and Critical Limb Ischemia (CLI) ●Novel therapeutic approaches ●Predictive animal models e.g. innovative imaging techniques ●New biomarkers Acute/Intensive Care e.g. Acute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS), Acute Kidney Injury (AKI), Disseminated Intravascular Coagulation (DIC) ●Novel therapeutic approaches ●Predictive animal models with respect to development state ●Identifying disease-stage specific biomarkers Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 10. TS – we serve your needs CARDIOLOGY –☑ Heart Diseases (Heart Failure, Atrial Fibrillation, Cardioprotection) Bayer Healthcare Pharmaceuticals’ goal with its Cardiology business is to sustainably protect people‘s heart and bloodstream, because Cardiovascular Diseases have become a severe problem in our society. Early diagnosis and therapy of cardiovascular diseases plays a significant role – this is why our research concentrates on innovative approaches for several heart and vascular diseases as well as anti-coagulants. As a research-based pharmaceutical company, Bayer Healthcare Pharmaceuticals continues to improve and protect heart function in patients with heart failure and other heart diseases as well as secondary forms of pulmonary hypertension. Focus of external search is on proprietary (small and biological) molecules (e.g. inhibitors), innovative approaches, new mechanism-of-action, state-of-the-art in-vitro, in-vivo and ex-vivo pharmacology models, and biomarkers for Heart Failure (HF) ●Novel therapeutic approaches for anti-remodeling, function improvement and diastolic HF ●Predictive animal models for remodeling processes and diastolic HF ●Sex and gender-specific models for heart diseases ●New biomarkers monitoring therapeutic success AFib Atrial Fibrillation (AF) ●Novel therapeutic approaches for rate and rhythm control AFi ●Predictive animal models Sinus rhythm b Sinus rhyth Cardioprotection (ischemia/reperfusion) m ●Novel therapeutic approaches for prophylaxis of cardiac injuries ●Predictive animal models for prim. and sec. prophylaxis ●New biomarkers (patient risk stratification for MACE) Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 11. TS – we serve your needs CARDIOLOGY –☑ Kidney Diseases (Diabetic Nephropathy, CKD, Acute Renal Insufficiency) Bayer Healthcare Pharmaceuticals’ goal with its Cardiology business is to sustainably protect people‘s heart and bloodstream, because Cardiovascular Diseases have become a severe problem in our society. Early diagnosis and therapy of cardiovascular diseases plays a significant role – this is why our research concentrates on innovative approaches for several heart and vascular diseases as well as anti-coagulants. As a research-based pharmaceutical company, Bayer Healthcare Pharmaceuticals continues to improve and protect renal function in patients with acute and chronic kidney dysfunction and insufficiency. Focus of external search is on proprietary (small and biological) molecules (e.g. inhibitors), innovative approaches, new mechanism-of-action, state-of-the-art in-vitro, in-vivo and ex-vivo pharmacology models, and biomarkers for Diabetic Nephropathy (DN) ●Novel therapeutic approaches to protect diabetic patients from developing and worsening of DN ●Predictive animal models ●Biomarkers for early monitoring of therapeutic success Chronic Kidney Disease (CKD) progression ●Novel therapeutic approaches ●Predictive animal models ●Biomarkers for early monitoring of therapeutic success Ischemia- or hypertension- induced CKD AFib ●Novel therapeutic approaches ●Predictive animal models Sinus rhythm ●Biomarkers for early monitoring of therapeutic success Cardiovascular Diseases associated with CKD Novel therapeutic approaches ● Predictive animal models and biomarkers ● Acute Renal Insufficiency ●Novel therapeutic approaches ●Predictive animal models ●Biomarkers for early monitoring of therapeutic success Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 12. TS – we serve your needs CARDIOLOGY –☑ Vascular Disease (Pulmonary Hypertension)Bayer Healthcare Pharmaceuticals’ goal with its Cardiology business is to sustainably protect people‘s heart, lungs andbloodstream, because Cardiovascular Diseases have become a severe problem in our society. Early diagnosis and therapy ofcardiovascular diseases plays a significant role – this is why our research concentrates on innovative approaches for severalheart, lung and vascular diseases as well as anti-coagulants.As a research-based pharmaceutical company, Bayer Healthcare Pharmaceuticals continues to improve and protect heartfunction in patients with heart failure and other heart diseases as well as primary & secondary forms of pulmonary hypertension.Focus of external search is on proprietary (small and biological) molecules (e.g. inhibitors), innovative approaches, newmechanism-of-action, state-of-the-art in-vitro, in-vivo and ex-vivo pharmacology models, and biomarkers for Pulmonary Arterial Hypertension (PAH) PAH despite recent therapeutic advances remains a deadly disease ● NO-deficiency can underlie treatment failure of PDE5-inh. ● ●New therapeutic approaches are of interest (target ideas) ●New biomarkers Secondary Pulmonary Hypertension (e.g. assoc. with lung diseases) ●Novel therapeutic approaches for sec. PH AFib ●Focus on the interaction of PH and underlying (lung) disease ●Predictive animal models for sec. PH ●Relevance of PH for underlying disease Sinus rhythm ●Subgroup analysis of pat. with secondary PH-forms incl. underlying diseases Arterial Hypertension ●Current Bayer portfolio offers upside potential towards art. hypertension ●Current focus: resistant art. Hypertension (rHT) ●Stratification of patients with rHT Chronic forms of peripheral vascular diseases ●Novel therapeutic approaches ●Predictive animal models e.g. innovative imaging techniques ●New biomarkers Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 13. TS – we serve your needs CARDIOLOGY – ☑ Hemoglobinopathies (Sickle Cell Disease, Beta-Thalassemia, Hemophilia A and B) Bayer Healthcare Pharmaceuticals’ goal with its Cardiology business is to sustainably protect people‘s heart, lungs and bloodstream, because Cardiovascular Diseases have become a severe problem in our society. Early diagnosis and therapy of cardiovascular diseases plays a significant role – this is why our research concentrates on innovative approaches for several heart, lung and vascular diseases as well as anti-coagulants. Leverage hematology / cardiology expertise, particularly in disease complication modeling, with hemophilia core knowledge to enter new indications in hemoglobinopathies. Focus of external search is on proprietary (small and biological) molecules (e.g. inhibitors), innovative approaches, new mechanism-of-action, state-of-the-art in-vitro, in-vivo and ex-vivo pharmacology models, and biomarkers for Bayer’s cardiology compounds in development ●Novel antithrombotics in thrombosis indications e.g. anticoagulant rivaroxaban (Xarelto®) ●sGC – modulator franchise: frontrunner riociguat in phase III studies in pulmonary hypertensionBayer seeks to pursue hemoglobinopathies through collaborative partnerships leveraging partner’s scientific know-how and Bayer’s expertise. Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 14. TS – we serve your needs Oncology (updated 06-2012)Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing#* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 15. TS – we serve your needs☑ ONCOLOGY / GYNECOLOGICAL THERAPIES (innovative therapies for solid tumors) The vision of the oncology research at Bayer Healthcare Pharmaceuticals is to improve the lives of patients affected by cancer. Our pipeline offers therapies for both solid tumors (e.g. prostate, liver, colon, breast, kidney, lung, gastric and pancreatic cancer) and benign hyper-proliferative diseases (e.g. uterine fibroids, endometriosis). It includes innovative therapeutic strategies for the inhibition of tumor growth and cell proliferation using small molecule compounds (e.g. kinase inhibitors) and biological compounds (e.g. antibody drug conjugates (ADC), and function blocking antibodies. Beyond our own research efforts, we cooperate in multiple partnerships with health care professionals, universities, academic research centers, other pharmaceutical companies, and innovative biotechnology organizations. Our solid relationships with the scientific community foster an open exchange of ideas and information and help to expand our vision of treatment. Focus of external search is on proprietary new targets and tools, small molecules (e.g. kinase inhibitors), proteins (e.g. antibodies), plasmids and cell lines, in-vitro technologies for functional analyses and animal models in the fields of Cell cycle / Survival Signaling ● Cell cycle inhibition ● Tumor cell selective induction of apoptosis or other forms of cell death Disease-relevant & predictive Chromatin Modulation and OncoGenomics animal models for Transcription and chromatin modulators ● ● all types of cancer Specific antagonism/suppression of steroid receptors ● ● tumor metabolism ● triggering immune responses Tumor Metabolism ● Inhibition of tumor metabolism 3D-in-vitro technologies ● Selective targeting of tumor-specific metabolic dependencies ● Cell/cell and Cell/ECM interactions Cancer Immune Therapy and Antibody Drug Conjugates (ADCs) ●by counteracting immunosuppressive activities (e.g. immune checkpoint inhibition) ●by actively triggering immune response (e.g. BiTE) ●by selective killing of tumor cells using antibody drug conjugates (ADCs) Hyper-proliferative Diseases ● Uterine fibroids ● Endometriosis / adenomyosis uteri Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 16. TS – we serve your needs☑ ONCOLOGY / GYNECOLOGICAL THERAPIES (innovative therapies for solid tumors) Bayer Oncology Research AreasTumor Cell Cycle & Chromatin Cancer StemMetabolism & Survival Signaling Modulation CellsHypoxia Antibody-Drug Cancer Conjugates Immuno- therapy Cancer Genomics Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 17. Bayer HealthCare Pharmaceuticals Dr. Jörg KnäbleinResearch Focus TECHNOLOGY SCOUTING Bayer Healthcare PharmaceuticalsTECHNOLOGY SCOUTING (TS) Phone: +49 30 4681 6852 Mobile: +49 160 972 06850– presentation available upon request E-mail: joerg.knaeblein@bayer.com Cardiology Oncology Pulmonary Hypertension / ● Cell Cycle / Survival Signaling ● Heart Failure ●Immunotherapy / Antibody- ●Thrombosis / Acute Coronary Drug Conjugates Syndrome ●Tumor Metabolism / Hypoxia ●Cardiorenal Syndrome (CRS) ●Chromatin Modulation / OncoGenomics Hematology Gynecological Therapy ●Anemia and other blood diseases ● Endometriosis ●LCM long acting factor VIII - Uterine Fibroids Common Mechanism Research & Other Areas ●Leveraging the full potential of development compounds ●Ophthalmology ●Inflammation ●LCM Fertility Control / Menopause-Management ●Magnetic Resonance and Computed Tomography Contrast Media Research Page * Global Innovation Sourcing • – February 2012
  • 18. TS – we serve your needs Reasons to Partner with BayerDr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing#* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 19. BHC Global Innovation Sourcing We Talk Understand and Live Science Business Partnerships , , !Page * • Global Innovation Sourcing • – February 2012
  • 20. Our Strengths Proven track record in identifying and optimizing innovative SMOL ● leads ●One of the world‘s largest compound library (∼ 3 million cpds) ●Ultra-high-throughput compound screening platform in 1536-well format ●HT protein optimization platform ●Human antibody / antibody-drug conjugate technology ●Protein analytics and clinical manufacturing ●Excellent cardiology pharmacology with long experience ●Strong oncology expertise with focus on `first in class´ molecules ●Well established oncology networkWe want to share our experience with external innovative partnersPage * • Global Innovation Sourcing – February 2012
  • 21. Reasons to partner with Bayer ●We want to add real value to the compound or therapeutic area ●We are flexible regarding collaboration terms and models ●We leave our partners room to develop and prosper ●We put emphasis on strong alliance management ●We have excellent research and manufacturing capabilities ●We are responsive and committed during the entire partnering ●We compensate adequatelyBayer HealthCare has a proven track record of successful partnershipsPage * • Global Innovation Sourcing • – February 2012
  • 22. Bayer – Already A SelectedPartner of Choice For Many Development/ Distribution Discovery/ Technologies You are welcome to join us!Page * • Global Innovation Sourcing • – February 2012
  • 23. Bayer Pharma‘s „From Targets To Novel Drugs“ Initiative
  • 24. TS – we serve your needs Overview: Bayer HealthCareDr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing#* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 25. Bayer HealthCare’s Top-Selling Productsof Today Sales FY2010, currency-adjusted, € mio.Page * • Global Innovation Sourcing – February 2012
  • 26. Bayer: Science For A Better LifeSales 2010Bayer MaterialScience Bayer HealthCare (BHC) €10.1 billion €17 billion 28.9% 54.2%Bayer CropScience 19.5% €6.8 billionPage * • Global Innovation Sourcing – February 2012
  • 27. Thank you!
  • 28. Forward-Looking StatementsThis presentation may contain forward-looking statements based on currentassumptions and forecasts made by Bayer Group or subgroup management.Various known and unknown risks, uncertainties and other factors could lead tomaterial differences between the actual future results, financial situation,development or performance of the company and the estimates given here.These factors include those discussed in Bayer’s public reports which areavailable on the Bayer website at www.bayer.com.The company assumes no liability whatsoever to update these forward-lookingstatements or to conform them to future events or developments.Page * Bayer HealthCare Overview – February 2012
  • 29. TECHNOLOGY SCOUTING (TS) – we serve your needs Dr. Jörg Knäblein TECHNOLOGY SCOUTING, Global Innovation Sourcing Bayer HealthCare Pharmaceuticals; Berlin, S107, 01, 117 Phone: +49 30 468-1 6852; Fax: +49 30 468-9 6852 Mobile: +49 160 972 06850 E-mail: joerg.knaeblein@bayer.com Web: http://www.bayerpharma.deDr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing#* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 30. TS knows internal needs due to close interaction with BHCcommunity – utilized sources come from personal contacts TS is complementary to other Innovation Sourcing activities → value add is focus on “terra incognita” (unpublished) Scope: Source, identify & evaluate valuable Tech Offers / ASSETS (compounds, biomarker, TS addresses “Innovation Gap”: animal models, cells, biospecimens, maturity, communication, technologies, co-operations, projects) from and confidence academic groups world wide TS ●Conferences / Active Role Clients: ●Networking / Personal Contacts ●Reach Out / Efficient Trips Internal customers are from all indications & ●Educational Advertising / all sites: GTR, LGO, ER groups, BUs, but Trustful Scientist also GD; plus special requests from GPTs ●Leverage Internal Resources asking for specific (external) support Source: External key sources are academic research institutes, universities, TTOs, bioregions, databases, newsletters, publications, meetings, site-visits, conferences and – personal communication Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 31. Unique Selling Proposition of TS is access to ASSETS notyet published – enabled by global network of personalcontacts Trust & scientific acceptance → ASSETS from invisible “terra incognita”ASSETS Evolution of scouting strategy passi acti proactiv focuse ve ve e d receiving screen ask specific request offers databases TTOs directly @experts visibl invisible “terra t e incognita” Focused Scouting: specific requests at personal contacts yield maximum ASSETS Focused search in continuously extended network. Ask for specific technologies at appropriate partners. Follow-up with experts for other possible sources. Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 32. TS communication / interfaces essential to get ASSETS:“Tell sources what BHC needs – and BHC what sources have” Sources/Offer BHC Needs s ●Research institutes pus pus ●ER groups, BUs ●Universities / TTOs ●GPTs, h h individuals pull pull GDD Technology ScoutingExternal: Internal:TS Team Roomspresentationwhat BHC ●Summary of (PIx) ●“Target-specific”needs repositories Baye BHC what‘s r USA BD&L “identifier needed ” “multiplier“ CANADA DDI what‘s needed & JAPAN NBV what we have … ROW … BUs Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 33. TS uses precise, continuously updated, and very tightselection criteria to identify ASSETS: all indications, allcategories, all sites Rigorous filtering (e.g. 98% attrition @Filter One) yields in valuable Tech Offers → ASSETS Filter Filter Filter One: & precise Two: selected by Three: acceptable tight criteria BU/Functions conditions (e.g. resources) & sponsor > 10.000 Tech in-house @Bayer Offers Team Rooms ASSETS WIP (PIx) ONC WH DI CVAnimal ModelsBiomarker/ -BanksCell LinesCompoundsProjectsTechnologiesDr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing#* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 34. Bayer HealthCare Pharmaceuticals - Dr. Jörg Knäblein TECHNOLOGY SCOUTINGResearch Focus Bayer Healthcare PharmaceuticalsTECHNOLOGY SCOUTING (TS) Phone: +49 30 4681 6852 Mobile: +49 160 972 06850– presentation available upon request E-mail: joerg.knaeblein@bayer.com Cardiology Oncology Pulmonary Hypertension / ● Cell Cycle / Survival Signaling ● Heart Failure ●Immunotherapy / Antibody- ●Thrombosis / Acute Coronary Drug Conjugates Syndrome ●Tumor Metabolism / Hypoxia ●Cardiorenal Syndrome (CRS) ●Chromatin Modulation / OncoGenomics Hematology Gynecological Therapy ●Anemia and other blood diseases ● Endometriosis ●LCM long acting factor VIII - Uterine Fibroids Common Mechanism Research & Other Areas ●Leveraging the full potential of development compounds ●Ophthalmology ●Inflammation ●LCM Fertility Control / Menopause-Management ●Magnetic Resonance and Computed Tomography Contrast Media Research Page * Global Innovation Sourcing • – February 2012
  • 35. TechTransfer InitiativeDr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing#* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 36. TECHNOLOGYSCOUTING (TS) – Meeting in Berlin in upon request TECHNOLOGY TRANSFER – presentation available August 2011 Pharma perspective on TechTransfer in Germany Attendies ●Manfred Horst (MSD) ●Jörg Knäblein (Bayer) ●Marcus Kostka (Boehringer Ingelheim) ●Ralph Kray (Johns Hopkins Business School) ●Lucks (Novartis) ●Hüls (MerckSerono) ●Burkhard Fugmann (BIG) Best practice sharing - TTO and Pharma Common understanding of optimization potential ●No harmonized clear dataset for technology offers – highly diverse ●Technology transfer professional: skills, edjucational background, motivationand overview on research activities ●No existing central portal to access all existing technology offers ●PVA´s not acting as central business partner for Pharma ●Optimization of training for TTO professionals (Curriculum) Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 37. TECHNOLOGY TRANSFER – proposal for standardized TechOffers SCOUTING (TS) – presentation available upon request TECHNOLOGY Standardization of TechOffers (content / data / info / format)Prerequisite – all data and information non-confidential1. Summary of mode of action, target or new pathway/mechanism in the context of relevant indication2. Summary of the most important biology/pharmacology data including the status of the in vivo efficacy profile3. Information about type of opportunity – NCE/NBE vs method/assay vs technology (drug delivery, formulation etc)4. If NCE/NBE overview on compound profiling status (DMPK, CMC, Tox, Gen Pharm)5. IP – status and owner of patent applications6. Further information – citation of relevant publications, patents, or links Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 38. TECHNOLOGY TRANSFER – proposal for standardized TechOffers SCOUTING (TS) – presentation available upon request TECHNOLOGY Standardization of TechOffers (content / data / info / format)Additional points to consider for TechTransfer – at a later stage1. Business model a) License model for Foreground IP (created during collaboration): university to own with NERF (non-exclusive royalty free) license to sponsor + option for exclusivity to sponsor OR all to sponsor with license? b) License model for Background IP: milestones, option for exclusivity?2. Payment for development activities: effort (man hours, consumables etc) or fixed package? Milestone based?3. Insight into cost structure (separating actual cost from overhead)Points for discussion:1. Proposal of technology transfer portal (communication platform) with standardized and up to date opportunities2. Proposal on harmonizing technology transfer by using the existing PVA´s per state with respective professional skills and education3. Improvement of skills by continues training of technology transfer professions at academia and institutes4. Start dialogue with academic partners on TT optimization on both ends Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 39. TECHNOLOGY TRANSFER – additional thoughts from pharma colleagues TECHNOLOGY SCOUTING (TS) – presentation available upon request Standardization of TechTransfer (content / data / info / format)Create market placethe place to look to get away from “accidental” identification of opportunitiesHarmonization is alsothe “management of expectations” at both endsSkill setBesides the “jack of all trades device” for BAT IIa we wish the following:Non dogmatic, pragmatic personality (tough to train, but very important)Excellent negotiation skills (Harvard Business School training or equivalent)●Sound understanding of pharmaceutical development processes●Understanding of work in a highly regulated environment (GLP, GMP, GCP etc.)●Sound understanding of IP principles including “Employee Inventions Act”●Basics of “Contracting” & Legal language Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 40. TECHNOLOGY SCOUTING (TS) – presentation available upon request TECHNOLOGY TRANSFER – current status Standardization of TechTransfer (content / data / info / format)Meeting held with TT managers from academia 21st Sep 2011These "areas of improvement„ (worked out from a pharma perspective) werepresented at a meeting with academic patent commercialization agencies(4. Treffen der Arbeitsgruppe Technologietransfer) on Wednesday, 21st ofSeptember 2011 in Mannheim.This initiative to improve Tech Transfer between academia and industry was verymuch appreciated by all participants.Joint meeting with managers from academia and industry 17th of Nov 2011Due to the success of the Mannheim meeting and the importance of this topic,attendees asked to organize another exchange forum for academia and industry tointensify and improve Tech Transfer .This meeting was held on the 17th of at Bayer in Düsseldorf. Besides colleagues fromBayer, BI, Merck, and Novartis, essentially ALL German patent commercializationagencies attended. This was judged as indicator for the importance of tis initiative. Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 41. TECHNOLOGY SCOUTING (TS) – presentation available upon request TECHNOLOGY TRANSFER – next steps Standardization of TechTransfer (content / data / info / format)Next meeting with EuKTS planned for 7th Mar 2012 in MnunichAs an important next step we have planned discussions with BMBF (FederalMinistry of Education and Research) to ensure a specific pharma TechTransfercurriculum and its region wide establishment.Also it is planned to closely interact with the European Knowledge Society (EuKTS)to harmonize all efforts and bring the TechTransfer initiative on a European level.A meeting with industry representatives from the TechTransfer initiative andacademic representatives from the German patent commercialization agencies willbe held on 7th of March in Munich. Here we will discuss a joint strategy withrepresentatives from EuKTS. Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 42. TECHNOLOGY TRANSFER – presentation available upon request TECHNOLOGY SCOUTING (TS) – proposal for TT Curriculum (1/2) TT Curriculum for TT offices and companiesA. Innovation1. Discovery and invention process kindly provided by2. Product design and innovation Johns Hopkins3. Managing the innovation process in a companyB. Intellectual Property1. Concept of intellectual property and different type of IP2. Patenting, what constitutes something that can be patented3. Patent landscaping4. Patent claims and patenting strategyC. Market Research1. Market research (purpose and types)2. Most common techniques of market research (focus groups, user surveys, conjoint analysis, potential customer surveys)3. Estimating market size and market growth Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 43. TECHNOLOGY TRANSFER – presentation available upon request TECHNOLOGY SCOUTING (TS) – proposal for TT Curriculum (2/2) TT Curriculum for TT offices and companiesD. Go-to-Market Strategies1. Types of go to market strategies (start up, merger/acquisition, license)2. Valuation of the IP3. Financing the go-to-market strategy (sources of financing and costs)E. Business Planning1. Concept of the business model2. Writing the business plan: key elements3. The Elevator Pitch4. Governance and ownership structure of the company Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing #* +49 30 468 1 6852, joerg.knaeblein@bayer.com
  • 44. Global Innovation Sourcing Partnering Activities @ Global Drug DiscoveryPage * • Global Innovation Sourcing – February 2012
  • 45. Bayer HealthCareDivisionsPage * • Global Innovation Sourcing – February 2012
  • 46. Bayer HealthCareResearch at a Glance Berli Wuppertal / Cologne Berkeley / Beijin n / San g Monheim Francisco Oncology ● Cardiology ● ●Hematology ●GDD Innovation Women’s ● Oncology ● ●Biologics Research & Center China Healthcare ●Biologics Research & Development ●Bayer Tsinghua ●Diagnostic Imaging Development ●Science Hub US Center for Innovative ●Animal Health Research Drug Discovery Investment in R&D 2010: € 1.8 billion ● ●Investment in R&D of 2010 total net sales: 16.1% ●R&D Employees: 6,200 (2010)Page * Global Innovation Sourcing • – February 2012
  • 47. Our R&D Pipeline Provides a Balanced Mix of NME and LCM Opportunities Phase I (10) Phase II (11) Phase III (19)Cancer CHF Ovarian/Peritoneal Cancer CRVO VTE TreatmentPI3K Inhibitor (BAY 80-6946) BAY 94-8862 (MR Sorafenib VEGF Trap-Eye RivaroxabanCancer Antagonist) Additional Indications Myopic CNV ACSCDK-Inhibitor (BAY 1000394) Pulmonary Hypertension Sorafenib VEGF Trap-Eye RivaroxabanCancer Riociguat (sGC Stimulator) Lung Infection DME NSCLCHIF1a – Inhibitor (BAY 97- Cancer Cipro inhale VEGF Trap-Eye Sorafenib2243) Regorafenib Gram-negative PAH Thyroid CancerCancer Cancer Pneumonia Riociguat (sGC SorafenibBAY 94-9343 (Mesothelin-ADC) BAY 86-9766 (MEK-Inhibitor) Amikacin inhale Stimulator) Breast CancerAnemia Bone Mets Breast Cancer CTEPH SorafenibBAY 85-3934 (HIF-PH) Alpharadin Riociguat (sGC MultipleSympt. Uterine Fibroids Atopic Dermatitis Stimulator) SclerosisBAY 1002670 (S-PRAnt) Mapracorat (SEGRA) CRC AlemtuzumabDiagnostic Imaging ED Regorafenib ContraceptionPET-Tracer BAY 60-4552/Vardenafil GIST LCS (ULD LNG)MCI Regorafenib ContraceptionBAY 94-9172 (Florbetaben) Alzheimer PET Imaging FC Patch LowHemophilia BAY 94-9172 (Florbetaben) MRI LCMBAY 94-9027 (peg rFVIII) Submental fat removal GadovistHemophilia ATX-101 VV AtrophyBAY 86-6150 (rFVIIa) Vaginorm New Molecular Entities (NME) Life Cycle Status as of October 2011 Management Table provides a selection of major pipeline projects of Bayer HealthCare (LCM) Page * Global Innovation Sourcing – February 2012
  • 48. Strong BHC Clinical Pipeline Phase I (9) Phase II (12) Phase III (19)Cancer / PI3K Inhibitor Cancer / Regorafenib NSCLC / SorafenibCancer / CDK Inhibitor Cancer / MEK-Inhibitor Thyroid Cancer / SorafenibCancer / HIF1a Inhibitor Bone Mets Breast Cancer / Alpharadin Breast Cancer / SorafenibAnemia / HIF-PH Ovarian / Peritoneal Cancer / Sorafenib CRC / RegorafenibHemophilia / BAY 94-9027 CRC / Sorafenib GIST / RegorafenibHemophilia / BAY 86-6150 Additional Indications / Sorafenib VTE Treatment / RivaroxabanSympt. Uterine Fibroids / S- CHF / MR Antagonist ACS / RivaroxabanPRAnt PH / Riociguat (sGC Stimulator) PAH / Riociguat (sGC Stimulator)MCI / Florbetaben ED / BAY 60-4552/Vardenafil CTEPH / Riociguat (sGCDiagnostic Imaging / PET-Tracer Atopic Dermatitis / Mapracorat (SEGRA) Stimulator) Lung Infection / Cipro DPI Myopic CNV / VEGF Trap-Eye Gram-negative Pneumonia / Amikacin DME / VEGF Trap-Eye inhale CRVO / VEGF Trap-Eye Contraception / LCS (ULD LNG) Contraception / FC Patch Low VV Atrophy / FSD / Vaginorm Oncology Cardiology/Hematolog MRI LCM / Gadovist y Women’s Multiple Sclerosis / Alemtuzumab Healthcare Diagnostic Submental fat removal / ATX-101 Imaging Ophthalmolog y Other sStatus as of July 2011Table provides a selection of major pipeline projects of Bayer HealthCarePage * • Global Innovation Sourcing – February 2012
  • 49. More Than 40% From In-Licensing OrTogether With External Partners Phase I (9) Phase II (12) Phase III (19)Cancer / PI3K Inhibitor Cancer / Regorafenib NSCLC / SorafenibCancer / CDK Inhibitor Cancer / MEK-Inhibitor Thyroid Cancer / SorafenibCancer / HIF1a Inhibitor Bone Mets Breast Cancer / Alpharadin Breast Cancer / SorafenibAnemia / HIF-PH Ovarian / Peritoneal Cancer / Sorafenib CRC / RegorafenibHemophilia / BAY 94-9027 CRC / Sorafenib GIST / RegorafenibHemophilia / BAY 86-6150 Additional Indications / Sorafenib VTE Treatment / RivaroxabanSympt. Uterine Fibroids / S- CHF / MR Antagonist ACS / RivaroxabanPRAnt PH / Riociguat (sGC Stimulator) PAH / Riociguat (sGC Stimulator)MCI / Florbetaben ED / BAY 60-4552/Vardenafil CTEPH / Riociguat (sGCDiagnostic Imaging / PET-Tracer Atopic Dermatitis / Mapracorat (SEGRA) Stimulator) Lung Infection / Cipro DPI Myopic CNV / VEGF Trap-Eye Gram-neg. Pneumonia / Amikacin DME / VEGF Trap-Eye inhale CRVO / VEGF Trap-Eye Contraception / LCS (ULD LNG) Contraception / FC Patch Low VV Atrophy / FSD / Vaginorm Oncology Cardiology/Hematolog MRI LCM / Gadovist y Women’s Multiple Sclerosis / Alemtuzumab Healthcare Diagnostic Submental fat removal / ATX-101 Imaging Ophthalmolog y Other sStatus as of July 2011Table provides a selection of major pipeline projects of Bayer HealthCarePage * • Global Innovation Sourcing – February 2012
  • 50. Companies harbor only a small portionof the biomedical knowledge Even with a budget of >1.5 billion €, BHC Pharmaceuticals R&D ●only represents <1% of the annual spending on biomedical R&Dglobally ●Closer relationship to partners in academia and biotech neededto make better use of the existing knowledge and to address themajor challenges in biomedical R&D ●Research collaborations with academic, small biotech firms orlarge pharmaceutical corporations are an integral element of ourinnovation strategy ●Collaborations in all phases of the value chain – from research to developmentand production to marketing.The Global Innovation Sourcing Team is your partner atBHC when it comes to discussions about early assets andtechnologies, for licensing as well as for out-partneringactivities.Page * • Global Innovation Sourcing • – February 2012
  • 51. Partnering Organization Works AlongThe Value Chain Lead Researc Pre- Clinical discovery Clin. TD h LD LO development Dev. Ph I Ph II Ph III Driven by scientific concepts and data Driven by clinical PoC data Innovation Business Sourcing development Access to projects and new sources of ● innovation through partnerships and licenses ●Innovative / flexible partnership models to find mutually beneficial solution ●Responsibility for licensing, out- partnering of early assets, collaborative researchPage * • Global Innovation Sourcing • – February 2012
  • 52. Feedback from Our Academic Partners Prof. Otmar D. Wiestler, Scientific Director of DKFZ, Heidelberg,Germany:“Bayer HealthCare is an ideal partner for German Cancer Research Center becauseit is committed to pursue innovative therapeutic concepts and invest in high-riskideas. We experience Bayer HealthCare as a reliable, highly competent partner withan open mindset. Our alliance clearly generates a win-win situation and can serve asa model for public-private partnerships in the biomedical field.” Prof. Wang, Moores UCSD Cancer Center, La Jolla,USA: are two advantages in the G4T program. The first being the speed with which“Therethe grant is funded. The second being the potential of further collaboration in thefuture to advance the common research interests between my laboratory andBayer AG.” Prof. Multhaup, Free University of Berlin,Germany:“We have experienced an excellent support by Bayer HealthCare Scientists and havehad encouraging discussions.”Page * • Global Innovation Sourcing • – February 2012
  • 53. Feedback from Our Biotech Partners Paul Hastings, President and CEO, OncoMedPharmaceuticals“We have greatly enjoyed working with Bayer on our Wnt Pathway partnership, whichwas forged in June 2010. The collaborative spirit of the interactions has resulted insignificant R&D progress, including our first antibody in the pathway (OMP-18R5)advancing to clinical testing earlier this year, and significant progress on our 2ndbiologic program and small molecule discovery efforts. This is a great example of howbiotech and pharma companies can bring the best of their respective talents toadvance innovation.” Jens Hennecke, Ph.D., SVP, Business Development,Micromet“Our collaboration with Bayer is built on trust and a shared desire to utilize the skillsand strengths of both organizations to develop a new therapy for prostate cancer. Weview Bayer to be an ideal partner on account of its expertise in oncology, sharedconviction in the promise of our technology, excellent collaborative spirit and ability toaggressively advance a product through development and onto the market. We arevery pleased with the rapid progress achieved so far under this collaboration since itsinception in 2009 and look forward to continuing to work together to ultimately treatcancer patients with BAY2010112 / MT112.”Page * • Global Innovation Sourcing – February 2012
  • 54. Some Examples in More Detail …OncoMed / Tumor Stem Cells Global strategic alliance signed in June 2010 ● Wnt ●Focus on the discovery, development and Pathwaycommercialization of novel anti-cancer stem cell Biologicstherapeutics targeting the Wnt signaling pathway ●Bayer with the option to exclusively licenseantibody and protein therapeutic productcandidates at any point up to the completion ofPhase I testing ●Bayer and OncoMed share technology andknow-how to discover and develop small moleculeinhibitors of the Wnt pathway Small Molecules ●FDA accepted OncoMed‘s IND filing for amonoclonal Anti-Frizzled antibody(OMP-18R5 ) in April 2011 Transcription onPage * • Global Innovation Sourcing – February 2012
  • 55. Some Examples … German CancerResearch Center Alliance First agreement signed in 2007, collaboration extended for another 3 years ●in 2011 ●German Cancer Research Center (DKFZ) as the largest biomedical oncology researchcenter in Europe ●Collaboration along the entire drug discovery and development value chain ●Novel risk and reward sharing approach to collaborate with joint financing(1 million Euro / year / partner) and project selection (currently >9 joint projects) ●Ideal partnership due to high strategic fit and complementary competencies Bench BedsidePage * • Global Innovation Sourcing • – February 2012
  • 56. Some Examples …Tsinghua University Beijing Comprehensive collaboration agreement signed in 2009 ● ●The 1st strategic partnership with long-term commitment to discover newtargets/molecules in China ●Tsinghua University is the No.1 university in China with the fastest growing life sciencedisciplines, led by world renowned structural biologist, Prof. Yigong Shi ●Bayer-Tsinghua Joint Research Center of Innovative Drug Discovery (BTC) founded Letter of Intent Signing, November BTC Inauguration Ceremony, June 2008 2009Page * • Global Innovation Sourcing – February 2012
  • 57. Some Examples … Grants4Targets Initiative Background ●Numerous targets exist, but are “invisible” for us ●The knowledge outside > inside Idea Join forces with academia and biotech start ups to translate innovative targets ● into drugs ●Provision of grants to evaluate and validate novel targets – “Grants 4 targets” Approach ●Easily accessible Internet site and submission tool ●Low bureaucratic burden for both partners ●Clear communication on “needs” – what are we looking for? ●Fast processing of requests Lead Target Lead Optim Preclinic Clinic Submissio Disco Generat i- al al n very ion zationhttp://www.grants4targets.com Page * • Global Innovation Sourcing • – February 2012
  • 58. Some Examples … The InnovativeMedicines Initiative (IMI) ●Biggest Public Private Partnership in Life Science; joint budget of €2billion ●Focus on efficacy in 5 disease areas, safety, knowledge managementandeducation & training ●IMI projects address key pre-competitive bottlenecks identified byPharma ●Public funding goes exclusively to non-pharma partners like academia,small and medium enterprises, patient organizations and regulators ProjectsPage * • Global Innovation Sourcing • – February 2012
  • 59. Conclusion Bayer HealthCare is committed to innovation ● ●Partnerships are key for being world-class in research & development ●Complementary skills and expertise offer excellent basis for future collaborations ●We look forward to establishing joint projects – to find and evaluatenew targets and define new treatment options for the benefit of patientsExternal innovation is a key component in our R&D strategyPage * • Global Innovation Sourcing – February 2012
  • 60. Global Partnering with Academiaand Industry Along the Value Chain Lead Target Pre- Clinical/PO Generation/ Discovery clinical C Optimization Innovative Medicines Initiative OncoMed Public private partnership between Corporate partnership on European Commission & Pharma cancer stem cell therapies German Cancer Center (DKFZ) Strategic partnership with jointArdea Tsinghua University financing; > 9 projects runningCorporate licensing of 10 collaborative projectsMEK inhibitors for cancer across therapeutic areas Singapore Multiple programs for diagnosis: treatment of Asian specific cancerGrants4Targets (Global)Online crowd sourcing; over 70 grants for new target research providedPage * • Global Innovation Sourcing – February 2012
  • 61. Small Molecule CandidateGeneration Platform Generation of innovative small molecule lead structures using ultra-high- ●throughput screening of a ca. 3 million compound library in 1536-well format,supported by structural biology, fragment based technologies, etc. ●Optimization of leads to development compounds with high clinicalsuccess rate, origin of marketed drugs like Nexavar® and Xarelto® ●Close collaboration with Global Biologics on drug-antibody conjugates Preclinical Clinic Target Compound Lead Lead Discovery Screening Generation Optimization Phase I DevelopmentCompound Collection, Medicinal Chemistry, Pharmacophore Structural Biology,High-Throughput and Automated Synthesis Informatics, ComputationalHigh-Content Screening and Purification Property Prediction ChemistryPage * • Global Innovation Sourcing – February 2012
  • 62. GDD-Global Biologics R&D Core capabilities Biologics Pipeline Coagulation factor (CF) ● Marketed engineering ●Human antibody technology ●HTP protein optimization ●Antibody drug conjugates, incl. analytics Post- and clinical manufacturing PoC VEGF Trap-Eye Alemtuzumab KG-PF Disease areas ●Oncology Research and Pre-clinical ●Hematology mAbs Engineered ●Cardiology CFs ●Gynecology IgG ●Ophthalmology antigen Toxophore Fab ADCsPage * • Global Innovation Sourcing – February 2012
  • 63. Common Mechanism ResearchPlatform Search for new indications for clinical development candidates using ●bioinformatic pathway analysis, data mining, phenotypic in vitro assays and invivo models ●Inflammation platform to explore development of compounds across multipleindications to identify an optimal path forward ●Identification of new therapeutics for age-related macular degeneration Preclinical Clinic Target Compound Lead Lead Discovery Screening Generation Optimization Phase I Development Bioinformatics platform, data mining Phenotypic in vivo (Phylosopher) in vitro Models PharmacologyPage * • Global Innovation Sourcing – February 2012
  • 64. Bayer Oncology Research●Addressing key pathomechanisms and novel treatmentparadigms with SMOL and monoclonal antibodies●In the top group in areas like antibody-drug-conjugates,cell cycle regulation and survival signaling●Strong interest in areas like tumor metabolism, hypoxia,chromatin modulation, oncogenomics, cancer stem cellsand cancer immunotherapy●Broad network of partners in academia and biotechPage * • Global Innovation Sourcing • – February 2012
  • 65. Bayer Cardiology Research●Over 20 years experience with cardiovascularpharmacology and the identification and optimization ofinnovative compounds such as Adalat®, Xarelto® andriociguat●Focused on heart diseases (heart failure, atrialfibrillation), vascular diseases (pulmonary hypertension)and acute care (thrombosis, acute coronary syndrome,ischemic stroke)●State-of-the-art in vivo pharmacology with disease-mirroring animal models for CV indications in8 different species from mouse to dog. Clinical methodsare used for the evaluation of compound efficacies whichcan then easily be translated into clinical studies●Broad network of KOLs and academic institutions in allfocus disease areasPage * • Global Innovation Sourcing – February 2012
  • 66. BHC Global Innovation Sourcing Science We Talk Understand and Live Partnership Business sPage * • Global Innovation Sourcing – February 2012
  • 67. Probability of success from research tomarket approval: <1% Evaluation Phase IV Drug research Preclinica Clinical / studies l trials Approval Lab and Phase I: 20-100 healthy (up to (more animal volunteers 2 years) than experiments 2 years) Phase II: 100-500 patients ➔ safety, dosing Phase III: 1,000-10,000 patients ➔ efficacy, adverse events 1 drug ap- proved by 10,000 <250 <5 Test compounds Test Test health compounds compounds authoritie s€ >1 billion0 2 4 6 8 1 1 1 1 1 Y 0 2 4 6 8 earsSource: based on PhRMA Profile Pharmaceutical Industry2010Page * Bayer HealthCare Overview – February 2012
  • 68. Improving R&D Efficiency and Maximizingthe Value of Transformational Late-StagePharmaceutical Pipeline Assets Establish Xarelto® (rivaroxaban) as an ideal ●anticoagulant with the potential to redefine the market ® ●Demonstrate Nexavar ’s potential as a pan-tumor drugand a building block of Bayer’s global oncology franchise ●Transform hemophilia market by developinga long-acting Kogenate® ●Establish a new paradigm in the treatment ofage-related macular degeneration with VEGF Trap-EyePage * Bayer HealthCare Overview • – February 2012
  • 69. Thank you!
  • 70. Page * Bayer HealthCare Overview – February 2012
  • 71. Forward-Looking StatementsThis presentation may contain forward-looking statements based on currentassumptions and forecasts made by Bayer Group or subgroup management.Various known and unknown risks, uncertainties and other factors could lead tomaterial differences between the actual future results, financial situation,development or performance of the company and the estimates given here.These factors include those discussed in Bayer’s public reports which areavailable on the Bayer website at www.bayer.com.The company assumes no liability whatsoever to update these forward-lookingstatements or to conform them to future events or developments.Page * Bayer HealthCare Overview – February 2012